Importantly, recently published data revealed that patients with hematological malignancies receiving allo-BMT from healthy donors harboring incidental DNMT3A mutations (most commonly loss-of-function) associated with asymptomatic clonal hematopoiesis of indeterminate potential (CHIP) have higher rates of chronic GVHD and lower risk of malignant relapse (14). Here, DNMT3A is linked to chronic graft versus host disease.